California Public Employees Retirement System Has $58.97 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

California Public Employees Retirement System lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 142,630 shares of the company's stock after selling 9,276 shares during the quarter. California Public Employees Retirement System owned approximately 0.17% of IDEXX Laboratories worth $58,969,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $25,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at about $31,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories in the 4th quarter worth about $41,000. Institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several analyst reports. Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Piper Sandler raised their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Remove Ads

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded down $17.03 on Friday, reaching $393.73. 1,635,645 shares of the company traded hands, compared to its average volume of 591,359. The stock has a market capitalization of $31.91 billion, a PE ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company's 50 day moving average is $436.39 and its 200-day moving average is $441.13. IDEXX Laboratories, Inc. has a fifty-two week low of $390.11 and a fifty-two week high of $548.88.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.